

**SEARCH REQUEST FORM****Scientific and Technical Information Center**

Requester's Full Name: R GITOMEN Examiner #: \_\_\_\_\_ Date: 6/16/04  
 Art Unit: 1651 Phone Number 30 \_\_\_\_\_ Serial Number: 09/998777  
 Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL  
3671

**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

\*\*\*\*\*

**STAFF USE ONLY**

	Type of Search	Vendors and cost where applicable
Searcher: <u>Noble</u>	NA Sequence (#) _____	STN <u>438</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: <u>6/24/04</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>30</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>0</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>270</u>	Other _____	Other (specify) _____



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number:** 1249248

**TO: Ralph J Gitomer**  
**Location: rem/3d65/3e71**  
**Art Unit: 1651**  
**Thursday, June 24, 2004**

**Case Serial Number: 09/995737**

**From: Noble Jarrell**  
**Location: Biotech-Chem Library**  
**Rem 1B71**  
**Phone: 272-2556**

**Noble.jarrell@uspto.gov**

### **Search Notes**



# STIC SEARCH RESULTS FEEDBACK FORM

## Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher* or contact:

Mary Hale, Information Branch Supervisor  
Remsen Bldg. 01 D86  
571-272-2507

## Voluntary Results Feedback Form

➤ I am an examiner in Workgroup:  Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature  
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



=&gt; d his

```

FILE 'HCAPLUS' ENTERED AT 08:12:40 ON 24 JUN 2004
L1 ( 14071)SEA FILE=HCAPLUS ABB=ON PLU=ON OPTICAL ACTIVITY+OLD,NT/CT
L2 ( 85)SEA FILE=HCAPLUS ABB=ON PLU=ON RAMAN OPTICAL ACTIVITY/CT
L3 ( 14)SEA FILE=HCAPLUS ABB=ON PLU=ON VIBRATIONAL OPTICAL ACTIVITY/C
L4 ( 5920)SEA FILE=HCAPLUS ABB=ON PLU=ON CHIRALITY/CT
L5 ( 606)SEA FILE=HCAPLUS ABB=ON PLU=ON MUTAROTATION/CT
L6 ( 699)SEA FILE=HCAPLUS ABB=ON PLU=ON ROTATIONAL SPECTRA/CT
L7 ( 9520)SEA FILE=HCAPLUS ABB=ON PLU=ON "CONCENTRATION (CONDITION)" +OL
L8 ( 3203)SEA FILE=HCAPLUS ABB=ON PLU=ON "CONCENTRATION (PROCESS)" +OLD,
L9 ( 4)SEA FILE=HCAPLUS ABB=ON PLU=ON MOLARITY/CT
L10 ( 10215)SEA FILE=HCAPLUS ABB=ON PLU=ON STANDARD SUBSTANCES, ANALYTICA
L11 ( 1 SEA FILE=HCAPLUS ABB=ON PLU=ON (L1 OR L2 OR L3 OR L4 OR L5 OR
L12 ( 9520)SEA FILE=HCAPLUS ABB=ON PLU=ON "CONCENTRATION (CONDITION)" +OL
L13 ( 3203)SEA FILE=HCAPLUS ABB=ON PLU=ON "CONCENTRATION (PROCESS)" +OLD,
L14 ( 4)SEA FILE=HCAPLUS ABB=ON PLU=ON MOLARITY/CT
L15 ( 10215)SEA FILE=HCAPLUS ABB=ON PLU=ON STANDARD SUBSTANCES, ANALYTICA
L16 ( 448069)SEA FILE=HCAPLUS ABB=ON PLU=ON SPECTRA+OLD,NT/CT
L17 ( 3)SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L12 OR L13 OR L14) AN
L18 ( 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (PY<=2001 OR PRY<=2001
L19 354 CIRCULAR DICHROISM SPECTROSCOPY/CT
L20 1782 COTTON EFFECT+OLD/CT
L21 18368 CIRCULAR DICHROISM+OLD,NT/CT
L22 3995 OPTICAL ROTATORY DISPERSION+OLD/CT
L23 57378 SPECTROMETERS+OLD,NT/CT
L24 1711 POLARIZED LIGHT/CT
L25 380 POLARIZED LUMINESCENCE/CT
L26 62854 POLARIZATION+OLD,NT/CT
L27 1330 L23-26 (L) (CIRCUL? OR ROTAT?)
L28 0 L7-9 AND L10 AND (L19 OR L20 OR L21 OR L22 OR L27)
L29 80 L7-9 AND L10
L30 4393 L23-26 (L) OPTIC?
L31 0 L29 AND L30
L32 8 L29 AND (?CIRCUL? OR ?OPTIC? (1A) ?ROTAT? OR ?POLAR? OR ?OPTIC?
L33 5 L32 NOT (L11 OR L18)
L34 25839 REAGENTS+NT/CT
    E BUCKE C/AU
L35 121 E3-7
    E ADLARD M/AU
L36 49 E4-8
    E SINGLETON V/AU
L37 7 E3,E13
    E HORN J/AU
L38 76 E3,E13,E56-57
L39 52 OPTICAL ACT?/CS,PA
L40 3056 L34 (L) ANST+NT/RL
L41 57 L40 AND L10
L42 1 L41 AND L35-38
L43 0 L41 AND L39
L44 56 L41 NOT L42
L45 49 L44 AND (PY<=2001 OR AY<=2001 OR PRY<=2001 OR AD<20011129 OR PD
L46 9 L45 AND L7-9
L47 26 (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L16 OR L19 OR L20 OR L21 O
L48 1 L47 AND L35-38
L49 0 L47 AND L39
L50 25 L47 NOT L48
L51 17 L50 AND (PY<=2001 OR AY<=2001 OR PRY<=2001 OR AD<20011129 OR PD
L52 0 L18 AND L34
L53 1 L51 AND DICHROISM DETECTION/TI

```

L54 72 (L1 OR L2 OR L3 OR L5 OR L6 OR L16 OR L19 OR L19 OR L20 OR L21  
L55 71 L54 NOT L35-38  
L56 0 L55 AND L39  
L57 65 L55 AND (PY<=2001 OR AY<=2001 OR PRY<=2001 OR PD<20011129 OR AD  
L58 2 L57 AND (STRUCTURE ELUCIDATION OR OPTICAL ROTATION)/TI  
L59 63 L57 NOT L58  
L60 2 L59 AND (SOLUBILITY-PH OR CIRCULAR DICHROISM)/TI  
L61 61 L59 NOT L60  
L62 4 L58 OR L60  
L63 218 (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L16 OR L19 OR L20 OR L21 O  
L64 1 L63 AND L35-38  
L65 0 L63 AND L39  
L66 217 L63 NOT L64  
L67 147 L66 AND (PY<=2001 OR AY<=2001 OR PRY<=2001 OR PD<20011129 OR AD  
L68 6 L67 AND (INCLUSION COMPLEXATION OR AFFINITY SEPARATION OR PURIF  
L69 141 L67 NOT L68  
L70 10 L69 AND (SPECTROSCOPIC PROBES OR BIREFRINGENCE OR CONCENTRATION  
L71 6 L70 NOT (CHIRAL OR GENERIC ALGORITHMS)/TI  
L72 4 L70 NOT L71  
L73 1 L72 AND BIREFRINGENCE/TI  
L74 7 L71 OR L73  
L75 5 L35-38 AND DEXTRAN/TI  
SEL AN DN 3-5  
L76 3 E1-9 AND L75  
SEL RE L76  
L77 18 E10-28  
L78 2 L77 AND (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L16 OR L19 OR L20  
L79 2 L78 AND L35-38  
L80 6 L74 NOT GENETIC ALGORITHMS/TI  
L81 114658 (?OPTIC? (L) (ROTAT? OR ACTIVIT?) OR CIRCUL? (L) DICHRO? OR ?PO  
L82 2330 L81 AND ?STANDARD?/BI  
L83 394 L82 AND ?CONCENTRAT?/BI  
L84 33 L83 AND (L34 OR ?REAG?/BI)  
L85 1 L84 AND L35-38  
L86 0 L84 AND L39  
L87 32 L84 NOT L85  
L88 32 L87 AND (PY<=2001 OR AY<=2001 OR PRY<=2001 OR PD<20011129 OR AD  
L89 9 L88 AND (POLARIMETRIC OR AROMATIZING OR SUCROSE OR OCTACORDINA  
SEL AN 2-5  
L90 4 E1-8 AND L89  
SEL AN 3  
L91 1 E9-10 AND L90

=> b hcap

FILE 'HCAPLUS' ENTERED AT 12:00:47 ON 24 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2004 VOL 140 ISS 26  
 FILE LAST UPDATED: 23 Jun 2004 (20040623/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:413992 HCAPLUS  
 DN 138:378287  
 ED Entered STN: 30 May 2003  
 TI A method for the measurement of the concentration of a material such as dextran or raffinose in a solution  
 IN Bucke, Christopher; Adlard, Max; Singleton, Victoria; Horn, Jennifer  
 PA UK  
 SO U.S. Pat. Appl. Publ., 9 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM C12Q001-34  
 ICS C12N009-24  
 NCL 435018000; 435200000  
 CC 80-6 (Organic Analytical Chemistry)  
 Section cross-reference(s): 9, 11, 17  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003100041	A1	20030529	US 2001-995737	20011129
	GB 2367617	A1	20020410	GB 2000-24299	20001004
	GB 2367617	B2	20040107		
PRAI	US 2001-995737	A	20011129		

AB A method for the measurement of the concentration of a material such as dextran or raffinose in a solution, notably a sugar solution, comprises the step of: i measurement of the optical rotation of a solution sample; ii treatment of the sample with a reactive agent, reactive with the material, sufficient to alter the optical rotation of the sample; iii measurement of the optical rotation of the sample after treatment; and iv calcn. of the concentration of the material by reference to a suitable standard

ST assay

IT Wavelength

(IR; method for measurement of concentration of a material such as dextran

or

raffinose in a solution)

IT Fruit and vegetable juices

(cane; method for measurement of concentration of a material such as dextran or raffinose in a solution)

IT Samples

(liquid; method for measurement of concentration of a material such as

dextran

or raffinose in a solution)

IT **Concentration (condition)**

Materials

Mathematical methods

Molecular weight

**Optical activity**

Particle size

Polarimetry

Solids

## Solutions

**Standard substances, analytical**

## Test kits

(method for measurement of concentration of a material such as dextran or raffinose in a solution)

IT Carbohydrates, analysis

RL: ANT (Analyte); ANST (Analytical study)

(method for measurement of concentration of a material such as dextran or raffinose in a solution)

IT Reagents

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)

(method for measurement of concentration of a material such as dextran or raffinose in a solution)

IT Diatomite

RL: ARU (Analytical role, unclassified); ANST (Analytical study)

(method for measurement of concentration of a material such as dextran or raffinose in a solution)

IT 57-50-1, Sucrose, analysis 512-69-6, Raffinose 9000-69-5, Pectin

9004-53-9, Dextrin 9004-54-0, Dextran, analysis 9014-63-5, Xylan

RL: ANT (Analyte); ANST (Analytical study)

(method for measurement of concentration of a material such as dextran or raffinose in a solution)

IT 9025-35-8,  $\alpha$ -Galactosidase 9025-70-1, Dextranase

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)

(method for measurement of concentration of a material such as dextran or raffinose in a solution)

=> d all 153 tot

L53 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:814738 HCAPLUS

DN 134:2319

ED Entered STN: 21 Nov 2000

TI Reagent and process for peptide/protein differentiation using circular  
**dichroism detection**

IN Purdie, Neil; Province, Dennis William

PA The Board of Regents for Oklahoma State University, USA

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N033-68

CC 9-5 (Biochemical Methods)

Section cross-reference(s): 6, 80

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068695	A2	20001116	WO 2000-US13246	20000512 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-134017P P 19990512 <--

AB A reagent comprised of an aqueous solution of Cu(II)-D-histidine complex acts effectively as a devitalizing agent required to qual. identify an

enantiomer and quant. determine its enantiomeric purities. The initial function of the host ligand (D-histidine) is to keep the Cu(II) ion in solution in high pH values. The base line CD spectrum associated with each Cu-(chiral ligand) host complex is uniquely different. On adding peptide or protein, exchange occurs between the host ligand (D-histidine) in the analyte ligand (protein). Exchanges produce changes in the CD spectrum that are significant enough that they have the potential of becoming a reliable spectroscopic fingerprint for every individual analyte.

- ST reagent peptide protein differentiation CD; copper histidine complex CD peptide protein
- IT Proteins, specific or class  
RL: ANT (Analyte); FMU (Formation, unclassified); PRP (Properties); ANST (Analytical study); FORM (Formation, nonpreparative)  
(complexes, with copper; reagent and process for peptide/protein differentiation using CD detection)
- IT Peptides, analysis  
RL: ANT (Analyte); FMU (Formation, unclassified); PRP (Properties); ANST (Analytical study); FORM (Formation, nonpreparative)  
(copper complexes; reagent and process for peptide/protein differentiation using CD detection)
- IT Algorithm  
**Circular dichroism**  
Pharmaceutical analysis  
Principal component analysis  
(reagent and process for peptide/protein differentiation using CD detection)
- IT Peptides, analysis  
Proteins, general, analysis  
RL: ANT (Analyte); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); ANST (Analytical study); PROC (Process); RACT (Reactant or reagent)  
(reagent and process for peptide/protein differentiation using CD detection)
- IT **Reagents**  
RL: **ARG (Analytical reagent use)**; RCT (Reactant); **ANST (Analytical study)**; RACT (Reactant or reagent); **USES (Uses)**  
(reagent and process for peptide/protein differentiation using CD detection)
- IT Protein sequences  
(validation of; reagent and process for peptide/protein differentiation using CD detection)
- IT 7681-11-0, Potassium iodide, analysis  
RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
(as stabilizer in reagent solution; reagent and process for peptide/protein differentiation using CD detection)
- IT 9004-10-8, Insulin, analysis  
RL: ANT (Analyte); PRP (Properties); RCT (Reactant); ANST (Analytical study); RACT (Reactant or reagent)  
(of human and bovine and porcine and recombinant; reagent and process for peptide/protein differentiation using CD detection)
- IT 556-50-3D, complex with Cu(II)      658-79-7D, complex with Cu(II)  
673-08-5D, complex with Cu(II)      687-69-4D, complex with Cu(II)  
691-81-6D, complex with Cu(II)      730-08-5D, complex with Cu(II)  
1050-28-8D, complex with Cu(II)      1187-50-4D, complex with Cu(II)  
1948-31-8D, complex with Cu(II)      3061-88-9D, complex with Cu(II)  
3695-73-6D, complex with Cu(II)      6234-26-0D, complex with Cu(II)  
7451-76-5D, complex with Cu(II)      7758-33-0D, complex with Cu(II)  
14857-82-0D, complex with Cu(II)      18625-22-4D, complex with Cu(II)  
19729-30-7D, complex with Cu(II)      21778-69-8D, complex with Cu(II)  
69242-40-6D, complex with Cu(II)      86030-53-7D, complex with Cu(II)



306275-69-4D, complex with Cu(II)

RL: ANT (Analyte); FMU (Formation, unclassified); PRP (Properties); ANST (Analytical study); FORM (Formation, nonpreparative)

(reagent and process for peptide/protein differentiation using CD detection)

IT 556-50-3 658-79-7 673-08-5 687-69-4 691-81-6 730-08-5  
1050-28-8 1187-50-4, L-Leucylglycylglycine 1948-31-8 3061-88-9  
3695-73-6 6234-26-0, Glycylglycyl-L-phenylalanine 7451-76-5,  
Glycylglycyl-L-histidine 7758-33-0, Glycyl-L-histidylglycine  
8049-62-5, Zinc insulin 14857-82-0, Glycylglycyl-L-leucine 18625-22-4,  
D-Leucylglycylglycine 19729-30-7, Glycylglycyl-L-alanine 21778-69-8,  
L-Tyrosylglycylglycine 69242-40-6, Glycylglycyl-L-isoleucine  
86030-53-7 306275-69-4

RL: ANT (Analyte); PRP (Properties); RCT (Reactant); ANST (Analytical study); RACT (Reactant or reagent)

(reagent and process for peptide/protein differentiation using CD detection)

IT 6341-24-8, D-Histidine hydrochloride

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)

(reagent and process for peptide/protein differentiation using CD detection)

IT 15158-11-9DP, Copper 2+, complex with peptides, preparation 308321-67-7P

RL: ARG (Analytical reagent use); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(reagent and process for peptide/protein differentiation using CD detection)

IT 60617-12-1D,  $\beta$ -Endorphin, complexes with copper(II)

RL: PRP (Properties)

(reagent and process for peptide/protein differentiation using CD detection)

IT 351-50-8, D-Histidine 1310-73-2, Sodium hydroxide, uses 7758-98-7, Copper sulfate, uses

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
(reagent solution containing; reagent and process for peptide/protein differentiation using CD detection)

=> d all 162 tot

L62: ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:566862 HCAPLUS

DN 135:132414

ED Entered STN: 06 Aug 2001

TI Method and device for measurement of **solubility-pH**  
profiles for drug screening

IN Avdeef, Alex; Tsinman, Konstantin L.

PA Pion, Inc., USA

SO PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM G01N021-33

CC 1-1 (Pharmacology)

Section cross-reference(s): 9

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055698	A1	20010802	WO 2001-US2377	20010125 <--
	W: JP				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR

US 2002004244 A1 20020110 US 2001-769570 20010125 <--

US 6569686 B2 20030527

EP 1250587 A1 20021023 EP 2001-903291 20010125 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI, CY, TR

JP 2003521686 T2 20030715 JP 2001-555790 20010125 <--

PRAI US 2000-178616P P 20000128 <--

WO 2001-US2377 W 20010125 <--

AB The measurement of aqueous solubility in a high-throughput screening environment

plays an important role in the selection of the most promising drug candidate mols. in pharmaceutical research and development. The invention describes a method, a simple, robust, high-throughput screen, that is applicable for the determination of the equilibrium solubility of sparingly soluble compds. and

that may be used in pharmaceutical, biotechnol., and related industries. An anal. device has been designed to implement the solubility measurement technique. The basic method involves determining solubility of a compound by measuring

the UV spectrum of a reference solution of the compound, under conditions avoiding

or suppressing precipitation, and comparing it to the UV spectrum of a saturated

sample solution of the compound Variations of the basic method include: (a) making reference solns. either by dilution of the sample solution to the point where

precipitation is avoided, or by adding a water-miscible cosolvent to the sample solution so that precipitation is suppressed, and comparing the UV absorbances of the

compound under reference conditions to the compound in a saturated solution, (b) determining the

true aqueous solubility from the effect on the pKa that results from dissolving the

compound in an aqueous solution containing some DMSO (typically 0.1-5% volume/volume), and

(c) correcting concns. determined from the UV absorbance values for impurities.

ST app drug screening soly pH profile

IT Self-association

Surfactants

(anomaly caused by; solubility-pH profile method and apparatus for drug screening)

IT Bile acids

Phospholipids, miscellaneous

RL: MSC (Miscellaneous)

(anomaly caused by; solubility-pH profile method and apparatus for drug screening)

IT **Spectrometers**

(**circular** dichrometers; solubility-pH profile method and apparatus for drug screening)

IT Solvents

(cosolvents; solubility-pH profile method and apparatus for drug screening)

IT Ion pairs

(ion pair-forming counterions, anomaly caused by; solubility-pH profile method and apparatus for drug screening)

IT Counterions

(ion pair-forming, anomaly caused by; solubility-pH profile method and apparatus for drug screening)

$\alpha$ -crystallin is best classified as a mixed protein. In addition, increased temperature and concentration of  $\alpha$ -crystallin result in increased  $\alpha$ -helixes with a compensatory decrease in  $\beta$ -sheets. Such structural alterations in  $\alpha$ -crystallin may be functionally important during terminal differentiation of the lens fiber cells that is accompanied by increased protein concns. and its role as a chaperone-like protein.

ST crystallin alpha secondary structure UV CD

IT **Concentration (condition)**

Secondary structure

$\alpha$ -Helix

$\beta$ -Sheet

(effects of temperature and concentration on bovine lens  $\alpha$ -crystallin secondary structure: CD spectroscopic study)

IT **Circular dichroism**

(far UV; effects of temperature and concentration on bovine lens

$\alpha$ -crystallin

secondary structure: CD spectroscopic study)

IT Temperature effects, biological

(heat; effects of temperature and concentration on bovine lens  $\alpha$ -crystallin secondary structure: CD spectroscopic study)

IT Crystallins

RL: PRP (Properties)

( $\alpha$ -; effects of temperature and concentration on bovine lens

$\alpha$ -crystallin secondary structure: CD spectroscopic study)

=> d all 191 tot

L91 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1964:31815 HCAPLUS

DN 60:31815

OREF 60:5724h,5725a-c

ED Entered STN: 22 Apr 2001

TI Determination of **sucrose**, invert sugar, and raffinose in sugar solutions

AU Oikawa, S.

SO Seito Gijutsu Kenkyu Kaishi (1962), 11, 28-37

From: Sugar Ind. Abstr. 25(4), Abstr. No. 273(1963).

CODEN: SGIIKA6; ISSN: 0370-9841

DT Journal

LA Unavailable

CC 50 (Industrial Carbohydrates)

AB Beet products from Japanese factories may contain appreciable amts. of invert sugar. The method of double polarization (according to Jackson and Gillis, method III) and the paper chromatographic method of de Whalley as modified by Albon and Gross were compared for the analysis of beet molasses or thick juice. The paper chromatographic method was used in conjunction with the determination of total sugars by Ofner's method after inversion. Invert sugar was determined by Ofner's method in both cases. The normal solution was clarified before polarization by adding a neutral Pb acetate solution (40 ml. in 200 ml.) and de-leading with NH<sub>4</sub> phosphate, followed if necessary by decolorization of 20 ml. of normal solution in a column of Amberlite IRA-401 resin (Cl form) at 80° and dilution to 100 or 110 ml. Zn dust was used in some cases to decolorize the solution after acid inversion. The chromatograms were sprayed with naphtho-resorcinol **reagent** and dried at 90° for 10 min. The mean diameter of the raffinose spot (4-5 mm. on the starting line, for a 2- $\mu$ l. volume) increased linearly with increasing **concentration** of raffinose over the range 0.4-0.8%. Three **standard** spots of different known

**concns.** were prepared for comparison. The error of the paper chromatographic determination of raffinose was  $\leq 10\%$ . The double polarization method gave results in good agreement with theory, except in cases where the sp. **optical rotation** of invert sugar was abnormal owing to an increase in the ratio of glucose to fructose; in such cases the paper chromatographic method should be applied in order to calculate the polarization equivalent of the reducing sugars.

IT Sugars

(analysis, determination of invert sugar, raffinose and **sucrose** in sugar-manufacturing solns.)

IT 512-69-6, Raffinose 8013-17-0, Sugar, invert  
(determination of, in sugar-manufacturing solns.)

=> b home

FILE 'HOME' ENTERED AT 12:01:50 ON 24 JUN 2004

IT Ionization  
 (ionizable compds.; solubility-pH profile method and apparatus for drug screening)

IT Spectrometers  
 (light-scattering; solubility-pH profile method and apparatus for drug screening)

IT Polymers, miscellaneous  
 RL: MSC (Miscellaneous)  
 (non-ionizable, anomaly caused by; solubility-pH profile method and apparatus for drug screening)

IT **Optical activity**  
 Sensors  
 (optical rotation; solubility-pH profile method and apparatus for drug screening)

IT Acidity  
 (pKa; solubility-pH profile method and apparatus for drug screening)

IT Apparatus  
 Buffers  
**Circular dichroism spectroscopy**  
 Colorimeters  
 Colorimetry  
 Drug screening  
 Filtration  
 Fluorometers  
 Fluorometry  
 Light scattering  
 Polarimeters  
 Polarimetry  
 Precipitation (chemical)  
 Solubility  
 Spectrometers  
 Spectrophotometry  
**Standard solutions, analytical**  
 Titration  
 UV and visible spectrometers  
 UV and visible spectroscopy  
 pH  
 (solubility-pH profile method and apparatus for drug screening)

IT Polyoxyalkylenes, uses  
 RL: NUU (Other use, unclassified); USES (Uses)  
 (solubility-pH profile method and apparatus for drug screening)

IT 12619-70-4, Cyclodextrin  
 RL: MSC (Miscellaneous)  
 (anomaly caused by; solubility-pH profile method and apparatus for drug screening)

IT 50-48-6, Amitriptyline 50-53-3, Chlorpromazine, biological studies  
 53-86-1, Indomethacin 54-31-9, Furosemide 57-66-9, Probenecid  
 72-69-5, Nortriptyline 93-09-4, 2-Naphthoic acid 94-78-0,  
 Phenazopyridine 126-07-8, Griseofulvin 525-66-6, Propranolol  
 2609-46-3, Amiloride 15307-86-5, Diclofenac 22916-47-8, Miconazole  
 36322-90-4, Piroxicam 50679-08-8, Terfenadine  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (solubility-pH profile method and apparatus for drug screening)

IT 67-68-5, DMSO, uses  
 RL: MSC (Miscellaneous); NUU (Other use, unclassified); USES (Uses)  
 (solubility-pH profile method and apparatus for drug screening)

IT 57-55-6, Propylene glycol, uses 64-17-5, Ethanol, uses 64-19-7, Acetic acid, uses 67-56-1, Methanol, uses 67-63-0, Isopropanol, uses 67-64-1, Acetone, uses 68-12-2, Dimethylformamide, uses 71-23-8, 1-Propanol, uses 75-05-8, Acetonitrile, uses 79-14-1, Glycolic acid, uses 107-21-1, Ethylene glycol, uses 107-35-7, Taurine 109-99-9, Tetrahydrofuran, uses 123-91-1, 1,4-Dioxane, uses 127-09-3, Sodium acetate 4432-31-9, MES 7365-45-9, HEPES 7732-18-5, Water, uses 10043-35-3, Boric acid, uses 25322-68-3, Polyethylene glycol 145224-94-8

RL: NUU (Other use, unclassified); USES (Uses)

(solubility-pH profile method and apparatus for drug screening)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bevan, C; WO 9913328 A 1999 HCAPLUS

(2) Lipinski, C; ADVANCED DRUG DELIVERY REVIEWS 1997, V23(1/03), P3

(3) Meserole, F; US 4906580 A 1990

L62 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:497393 HCAPLUS

DN 131:282611

ED Entered STN: 11 Aug 1999

TI **Structure Elucidation** of the Adducts Formed by Fjord-Region Dibenzo[a,l]pyrene 11,12-Dihydrodiol 13,14-Epoxides and Deoxyadenosine

AU Li, Kai-Ming; George, Mathai; Gross, Michael L.; Seidel, Albrecht; Luch, Andreas; Rogan, Eleanor G.; Cavalieri, Ercole L.

CS Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA

SO Chemical Research in Toxicology (1999), 12(9), 758-767

CODEN: CRTOEC; ISSN: 0893-228X

PB American Chemical Society

DT Journal

LA English

CC 4-6 (Toxicology)

Section cross-reference(s): 9

AB Model adducts to be used in the identification of biol. formed adducts were synthesized by reaction of fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides (DB[a,l]PDE) and deoxyadenosine (dA). The (+)-anti-DB[a,l]PDE was reacted with dA in DMF at 100 °C for 30 min to give four DB[a,l]PDE-14-N6dA adducts: (-)-anti-trans (26%), (+)-anti-trans (26%), (-)-anti-cis (17%), and (+)-anti-cis (17%). The (+)-syn-DB[a,l]PDE was reacted with dA under the same conditions to yield four DB[a,l]PDE-14-N6dA adducts and one N7Ad adduct: (+)-syn-cis (19%), (+)-syn-trans (13%), (-)-syn-cis (19%), (-)-syn-trans (13%), and (+)-syn-DB[a,l]PDE-14-N7Ad (22%). The structures of the eight stereoisomers of DB[a,l]PDE-14-N6dA were unequivocally assigned by reacting optically pure (-)-anti-DB[a,l]PDE and (+)-syn-DB[a,l]PDE with dA and by a combination of NMR, CD, and fast atom bombardment mass spectrometry. Reactions at 100 °C yielded mainly the trans-opened adducts at the benzylic C-14 position for both (+)-anti-DB[a,l]PDE and (-)-anti-DB[a,l]PDE, whereas (+)-syn-DB[a,l]PDE and (+)-syn-DB[a,l]PDE afforded mainly cis-opened adducts. At room temperature, however, only trans-opened adducts were obtained from (+)-anti-DB[a,l]PDE and only cis-opened adducts from (+)-syn-DB[a,l]PDE. Steric hindrance created by the fjord region may be an important factor for the stereoselectivity observed at room temperature

ST DNA adduct dibenzopyrenedi hydrodiol epoxide deoxyadenosine structure; mol model DNA adduct dibenzopyrenedi hydrodiol epoxide deoxyadenosine structure; Fjord region DNA adduct dibenzopyrenedi hydrodiol epoxide deoxyadenosine structure

IT DNA  
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)  
 (adducts; structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

IT Xenobiotics  
 (metabolism, metabolic activation; structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

IT Carcinogens  
 Circular dichroism spectroscopy  
 Fast atom bombardment mass spectrometry  
 Genotoxicity  
 HPLC  
 Molecular modeling  
 NMR (nuclear magnetic resonance)  
 Neoplasm  
 Skin, neoplasm  
 Standard substances, analytical  
 Stereochemistry  
 (structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

IT 958-09-8D, Deoxyadenosine, adducts with dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides 158414-00-7D, DNA adducts  
 RL: ADV (Adverse effect, including toxicity); ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)  
 (structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

IT 160180-24-5P 160180-27-8P 160227-19-0P 160227-20-3P 160227-21-4P 160227-22-5P 160227-23-6P 160227-24-7P 160227-25-8P  
 RL: ADV (Adverse effect, including toxicity); ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
 (structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

IT 153857-28-4 153926-04-6 158414-00-7  
 RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

IT 958-09-8, Deoxyadenosine  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (structure elucidation of the adducts formed by Fjord-region dibenzo[a,l]pyrene 11,12-dihydrodiol 13,14-epoxides and deoxyadenosine)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agarwal, S; J Am Chem Soc 1987, V109, P2497 HCAPLUS
- (2) Amin, S; Carcinogenesis 1995, V16, P1971 HCAPLUS
- (3) Amin, S; Carcinogenesis 1995, V16, P2813 HCAPLUS
- (4) Cavalicri, E; Carcinogenesis 1991, V12, P1939
- (5) Cavalieri, E; J Cancer Res Clin Oncol 1989, V115, P67 MEDLINE
- (6) Devanesan, P; Chem Res Toxicol 1999, V12, PXXX
- (7) Devanesan, P; Chem Res Toxicol 1999, V12, PXXX

- (8) Frank, H; Polycyclic Aromat Compd 1996, V10, P109 HCAPLUS
- (9) Gill, H; Carcinogenesis 1995, V15, P2455
- (10) Gross, M; Anal Chim Acta 1991, V250, P105 HCAPLUS
- (11) Higginbotham, S; Carcinogenesis 1993, V14, P875 HCAPLUS
- (12) LaVoie, E; Cancer Lett 1993, V70, P7 HCAPLUS
- (13) Lambert, J; Organic Structural Analysis 1976
- (14) Li, K; Biochemistry 1995, V34, P8043 HCAPLUS
- (15) Li, K; Chem Res Toxicol 1999, V12, PXXX
- (16) Luch, A; Chem Res Toxicol 1997, V10, P1161 HCAPLUS
- (17) Ralston, S; Cancer Res 1994, V54, P887 HCAPLUS
- (18) Ralston, S; Carcinogenesis 1995, V16, P2899 HCAPLUS
- (19) RamaKrishna, N; Chem Res Toxicol 1993, V6, P554 HCAPLUS
- (20) Szeliga, J; Chem Res Toxicol 1995, V8, P1014 HCAPLUS
- (21) Thakker, D; Stereochemical Aspects of Pharmacologically Active Compounds 1988, P271
- (22) US Government Printing Office; NIH Guidelines for the Laboratory Use of Chemical Carcinogens 1981

L62 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 1975:554886 HCAPLUS  
DN 83:154886  
ED Entered STN: 12 May 1984  
TI Recommended reference materials for realization of physicochemical properties. **Optical rotation**  
CS IUPAC Physical Chemistry Division, UK  
SO Pure and Applied Chemistry (1974), 40(3), 451-5  
CODEN: PACHAS; ISSN: 0033-4545  
DT Journal  
LA English  
CC 73-2 (Spectra by Absorption, Emission, Reflection, or Magnetic Resonance, and Other Optical Properties)  
AB Sucrose, anhydrous dextrose, and quartz are recommended as reference materials for  
optical rotation detns.  
ST optical rotation ref material  
IT **Optical rotation**  
(determination of, reference materials for)  
IT **Standard substances**  
(for optical rotation detns.)  
IT 50-99-7, uses and miscellaneous 57-50-1, uses and miscellaneous  
14808-60-7, uses and miscellaneous  
RL: USES (Uses)  
(reference material, for optical rotation detns.)

L62 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 1969:487296 HCAPLUS  
DN 71:87296  
ED Entered STN: 12 May 1984  
TI Suggested preliminary standards for calibration of optical rotatory dispersion and **circular dichroism** instruments  
AU DeTar, DeLos F.  
CS Florida State Univ., Tallahassee, FL, USA  
SO Analytical Chemistry (1969), 41(11), 1406-8  
CODEN: ANCHAM; ISSN: 0003-2700  
DT Journal  
LA English  
CC 79 (Inorganic Analytical Chemistry)  
AB Two approaches have been used in the present study in an effort to define preliminary circular dichroism (C.D.) standards. The 1st involved a careful reexamn. of 10-camphorsulfonic acid by using the Kronig-Kramers



transform to compare O.R.D. and C.D. curves. The 2nd approach utilized Co(en)3I3.H2O, a compound relatively easy to prepared and resolve and 1 for which 3 independent sets of absolute rotation values have been reported. Experience has shown that the angle measuring portion of a recording spectropolarimeter may not be in correct adjustment, and that the error may be a function of the full scale reading. This section of the instrument should, therefore, be checked against suitable O.R.D. standards before attempting to use O.R.D. value to establish a C.D. calibration. It is clearly undesirable to use ordinary uv or visible spectrometric values as a substitute for polarimetric values in deciding the optical purity of an intended standard.

ST standards circular dichroism; circular dichroism standards; ORD comparison  
circular dichroism; calibration circular dichroism; cobalt complexes  
circular dichroism; camphorsulfonic acid circular dichroism  
IT Dichroism  
(circular, preliminary standards for calibration in)  
IT **Standard substances**  
(for optical rotary dispersion)  
IT **Optical rotatory dispersion**  
(preliminary standards for calibration in)  
IT Ethylenediamine, cobalt complexes  
RL: PREP (Preparation)  
(preparation of)  
IT 5872-08-2 15405-85-3  
RL: ANST (Analytical study)  
(as preliminary standard for O.R.D.)

=> d all 180 tot

L80 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:886617 HCAPLUS  
DN 136:2464  
ED Entered STN: 07 Dec 2001  
TI System and method for the classification and of **biological**  
**samples** and their diagnostic potential  
IN Norgaard, Lars; Albrechtsen, Morten; Olsen, Ole Ingemann; Harrit, Niels;  
Bro-Jorgensen, Rasmus  
PA Medicometrics Aps, Den.  
SO PCT Int. Appl., 99 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM G01N021-64  
ICS A61B005-00  
CC 9-1 (Biochemical Methods)  
Section cross-reference(s): 14  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092859	A1	20011206	WO 2001-DK383	20010601 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

EP 1290428            A1    20030312            EP 2001-938006    20010601 <--  
           R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2003535330        T2    20031125            JP 2002-501018    20010601 <--  
 US 2003162301        A1    20030828            US 2003-297187    20030416 <--  
 PRAI DK 2000-863        A    20000602    <--  
 WO 2001-DK383        W    20010601    <--  
 AB    The invention concerns a method of training a classification system for  
       characterizing a biol. sample, a diagnostic classification system, as well  
       as a method of characterizing a condition in an animal or a human being by  
       using parameters obtained from the sample. The invention relates to  
       classification based on phys. parameters obtained from luminescence  
       spectroscopy on light emitted from the sample. The data obtained from a  
       spectrofluorimetric anal. can be considered a finger-print of the sample.  
       Each sample gives rise to a unique spectrofluorometric set of phys.  
       parameters. By analyzing the fluorescence data, it is possible to  
       classify samples into two or more classes based on the fluorescence  
       spectra, such as classifying with respect to presence/absence of a  
       specific disease, group of diseases or risk of later attaining a specific  
       disease or a body condition, or concentration of a specific compound or  
 medicine.  
 ST    analytical app system classifying biomol disease diagnosis chromatog  
       computer  
 IT    Aging, animal  
       Analytical apparatus  
       Animal  
       Animal tissue  
       Anisotropy  
       Bile  
       Biochemical molecules  
       Blood analysis  
       Blood plasma  
       Blood serum  
       Body fluid  
       Brain  
       Cerebrospinal fluid  
       Computer application  
       Computer program  
       **Concentration (condition)**  
       Diagnosis  
       Disease, animal  
       Eubacteria  
       Fasting  
       Feces  
       Fluorescence  
       Fluorometry  
       Hair  
       Heart, disease  
       Human  
       Kidney  
       Light sources  
       Liver  
       Luminescence spectroscopy  
       Lymph  
       Milk analysis  
       Muscle  
       Narcotics  
       Phosphorescence  
       Polarization  
       Saliva

Semen  
Sex  
Simulation and Modeling, physicochemical  
Skin  
Statistical analysis  
Stress, animal  
Sweat  
Tear (ocular fluid)  
Temperature effects, biological  
Tobacco smoke  
Urine analysis  
pH

(System and method for the classification and of biol. samples and their diagnostic potential)

IT Drugs of abuse

(abuse of; System and method for the classification and of biol. samples and their diagnostic potential)

IT Intestine, neoplasm

(colon; System and method for the classification and of biol. samples and their diagnostic potential)

IT **Circular dichroism**

(fluorescence-detected; System and method for the classification and of biol. samples and their diagnostic potential)

IT Mucus

(nasal; System and method for the classification and of biol. samples and their diagnostic potential)

IT Ecology

(population; System and method for the classification and of biol. samples and their diagnostic potential)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Instrumentation Metrics Inc; WO 0042907 A 2000
- (2) O'Brien, K; IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING 1989, V36(4), P424 MEDLINE
- (3) Rosenthal, R; US 5576544 A 1996 HCAPLUS
- (4) University Of Texas; WO 9630746 A 1996
- (5) University Of Texas; WO 9824369 A 1998

L80 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:310769 HCAPLUS

DN 133:89648

ED Entered STN: 14 May 2000

TI Measurements of **concentration dependence** and enantiomeric purity of terpene solutions as a test of a new commercial VCD spectrometer

AU Urbanova, Marie; Setnicka, Vladimir; Volka, Karel

CS Department of Physics and Measurement, Institute of Chemical Technology at Prague, Prague, 16628/6, Czech Rep.

SO Chirality (2000), 12(4), 199-203

CODEN: CHRLEP; ISSN: 0899-0042

PB Wiley-Liss, Inc.

DT Journal

LA English

CC 30-10 (Terpenes and Terpenoids)

Section cross-reference(s): 22

AB Vibrational CD (VCD) spectra of (+)- $\alpha$ -pinene solns. in carbon tetrachloride have been measured in the range of volume fractions 5-100% (volume/volume) in the mid-IR region. The concentration dependence measured

was

statistically analyzed with the aim of obtaining a reliable correlation

between the VCD band areas and the concns. of individual enantiomers. The quality of the spectra was estimated by means of noise spectra which were defined as half the difference of the two following blocks of scans. In addition to this, the enantiomeric purity was studied. This study was carried out for both (+)- and (-)- $\alpha$ -pinene enantiomers in the range of the percent enantiomeric excess in the interval 10-100%. The relationship between VCD intensity and enantiomeric purity was determined by least-square regression and statistically evaluated. All measurements performed in this study were intended as a basic tool for testing of a new com. VCD setup from Bruker.

ST terpene soln concn dependence enantiomeric purity VCD spectra; pinene soln concn dependence enantiomeric purity VCD spectra; limonene soln concn dependence enantiomeric purity VCD spectra; borneol soln concn dependence enantiomeric purity VCD spectra; least square regression analysis concn dependence terpene soln; statistical analysis concn dependence enantiomeric purity terpene soln

IT **Concentration (condition)**

(dependence; measurements of concentration dependence and enantiomeric purity of terpene solns. as a test of a new com. VCD spectrometer)

IT **Purity**

(enantiomeric; measurements of concentration dependence and enantiomeric purity of terpene solns. as a test of a new com. VCD spectrometer)

IT **Regression analysis**

(least-square; measurements of concentration dependence and enantiomeric purity of terpene solns. as a test of a new com. VCD spectrometer)

IT **Statistical analysis**

**Vibrational circular dichroism**

(measurements of concentration dependence and enantiomeric purity of terpene solns. as a test of a new com. VCD spectrometer)

IT **Terpenes, properties**

RL: PRP (Properties)

(measurements of concentration dependence and enantiomeric purity of terpene solns. as a test of a new com. VCD spectrometer)

IT 464-43-7, (+)-Borneol 464-45-9, (-)-Borneol 5989-27-5, (+)-Limonene  
5989-54-8, (-)-Limonene 7785-26-4, (-)- $\alpha$ -Pinene 7785-70-8,  
(+)- $\alpha$ -Pinene

RL: PRP (Properties)

(measurements of concentration dependence and enantiomeric purity of terpene solns. as a test of a new com. VCD spectrometer)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bormett, R; J Am Chem Soc 1992, V114, P6864 HCAPLUS
- (2) Bour, P; Chirality 2000, V12, P191 HCAPLUS
- (3) Bour, P; J Phys Chem A 1998, V102, P102 HCAPLUS
- (4) Freedman, T; Biopolymers 1995, V37, P265 HCAPLUS
- (5) Keiderling, T; Faraday Discuss Chem Soc 1994, V99, P263 HCAPLUS
- (6) Keiderling, T; Practical Fourier transform infrared spectroscopy. Industrial and laboratory chemical analysis 1990, P203
- (7) Lipp, E; Appl Spectrosc 1984, V38, P774 HCAPLUS
- (8) Long, F; Appl Spectrosc 1997, V51, P504 HCAPLUS
- (9) Nafie, L; Appl Spectrosc 1996, V50, P14A HCAPLUS
- (10) Nafie, L; Enantiomer 1998, V3, P283 MEDLINE
- (11) Nafie, L; Spectroscopy 1987, V2, P24 HCAPLUS
- (12) Pancoska, P; Biochemistry 1989, V28, P5917 HCAPLUS
- (13) Pancoska, P; Biochemistry 1991, V30, P5089 HCAPLUS
- (14) Polavarapu, P; Appl Spectrosc 1984, V38, P438 HCAPLUS
- (15) Setnicka, V; The Seventeenth Congress of Heterocyclic Chemistry 1999, PPO-110
- (16) Tsankov, D; Appl Spectrosc 1995, V49, P132 HCAPLUS

- (17) Urbanova, M; Biochemistry 1991, V30, P10479 HCAPLUS  
 (18) Urbanova, M; Biochim Biophys Acta 1993, V1203, P290 HCAPLUS  
 (19) Wang, B; Appl Spectrosc 1995, V49, P1347 HCAPLUS

L80 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:667657 HCAPLUS

DN 131:331311

ED Entered STN: 20 Oct 1999

TI The magneto-chiral **birefringence** in diamagnetic solutions and in uniaxial crystals

AU Kalugin, Nikolai G.; Kleindienst, Peter; Wagniere, Georges H.

CS Institute of Physical Chemistry, University of Zurich, Zurich, CH-8057, Switz.

SO Chemical Physics (1999), 248(1), 105-115

CODEN: CMPHC2; ISSN: 0301-0104

PB Elsevier Science B.V.

DT Journal

LA English

CC 77-8 (Magnetic Phenomena)

Section cross-reference(s): 22, 73

AB The interferometric measurement of the magneto-chiral birefringence is reported in several chiral organic solns. and in the chiral uniaxial crystals  $\alpha$ -quartz and LiIO<sub>3</sub> at a wavelength of 633 nm and in static magnetic fields of up to 5 T. The tech. details of the exptl. procedure are described in P. Kleindienst and G. Wagniere [Chemical Phys. Lett. 288(1998) 89]. The results are in agreement with the predicted selection rules. The orders of magnitude correlate with those for natural optical rotation and magnetic optical rotation. An unexpected behavior is found in LiIO<sub>3</sub> at fields .gtorsim.3 T, and its possible origins are discussed.

ST magneto-chiral birefringence diamagnetic soln uniaxial crystal; interferometer chiral org soln quartz lithium iodate crystal; selection rule magnetic field optical rotation

IT Birefringence

**Chirality**

**Concentration (condition)**

Diamagnetism

Interferometry

Magnetic field effects

**Optical activity**

Selection rule

Solutions

(magneto-chiral birefringence in diamagnetic solns. and in uniaxial crystals)

IT 147-85-3, Proline, properties 663-17-2 13765-03-2, Lithium iodate (LiIO<sub>3</sub>) 14808-60-7, Quartz, properties 35193-63-6 208193-31-1

RL: PRP (Properties)

(magneto-chiral birefringence in diamagnetic solns. and in uniaxial crystals)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aldrich Chemie; Aldrich Catalogue 1996
- (2) Anon; Beilsteins Handbuch der Organischen Chemie, 4th ed V7(part 4), P3301
- (3) Anon; Landolt-Bornstein, 6th ed 1950, V1(part 1), P409
- (4) Arnold, W; Tetrahedron Lett 1983, V24, P343 HCAPLUS
- (5) Barron, L; Mol Phys 1984, V51, P715 HCAPLUS
- (6) Haussuhl, S; Z Kristallogr 1988, V183, P153
- (7) Kleindienst, P; Chem Phys Lett 1998, V288, P89 HCAPLUS
- (8) Kleindienst, P; Doctoral Dissertation, University of Zurich 1999
- (9) Koralewski, M; Phys Status Solidi A 1980, V61, PK151 HCAPLUS
- (10) Markelov, V; JETP Lett 1977, V25, P378

- (11) Perekalina, Z; Sov Phys Crystallogr 1971, V15, P1095
- (12) Rikken, G; Nature (London) 1997, V390, P493 HCAPLUS
- (13) Rikken, G; Phys Rev E 1998, V58, P5081 HCAPLUS
- (14) Rykart, R; Quarz Monographie, Ott, Thun 1995, P307
- (15) Sands, D; Introduction to Crystallography 1969, P80
- (16) Surma, M; Mol Phys 1997, V90, P993 HCAPLUS
- (17) Surma, M; Mol Phys 1998, V93, P271 HCAPLUS
- (18) The Chemical Rubber Co; Handbook of Chemistry and Physics, 45th ed 1964, PC484
- (19) Wagniere, G; Chem Phys 1999, V245, P165 HCAPLUS
- (20) Wagniere, G; Z Naturforsch 1984, V39a, P254 HCAPLUS

L80 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:636351 HCAPLUS

DN 130:7353

ED Entered STN: 09 Oct 1998

TI Effect of **Tween 20** on Freeze-Thawing- and Agitation-Induced Aggregation of Recombinant Human Factor XIII

AU Kreilgaard, Lotte; Jones, LaToya S.; Randolph, Theodore W.; Frokjaer, Sven; Flink, James M.; Manning, Mark C.; Carpenter, John F.

CS The Department of Pharmaceutics, Royal Danish School of Pharmacy, Copenhagen, Den.

SO Journal of Pharmaceutical Sciences (1998), 87(12), 1597-1603

CODEN: JPMSAE; ISSN: 0022-3549

PB American Chemical Society

DT Journal

LA English

CC 63-5 (Pharmaceuticals)

AB Agitation- and freeze-thawing-induced aggregation of recombinant human factor XIII (rFXIII) is due to interfacial adsorption and denaturation at the air-liquid and ice-liquid interfaces. The aggregation pathway proceeds through soluble aggregates to formation of insol. aggregates regardless of the denaturing stimuli. A nonionic surfactant, Tween 20, greatly reduces the rate of formation of insol. aggregates as a function of surfactant concentration, thereby stabilizing native rFXIII. Maximum protection occurs at concns. close to the critical micelle concentration (cmc), independent of initial

protein concentration To study the mechanistic aspects of the surfactant-induced

stabilization, a series of spectroscopic studies were conducted. ESR spectroscopy indicates that binding is not occurring between Tween 20 and either the native state or a folding intermediate state of rFXIII. Further, CD spectroscopy suggests that Tween 20 does not prevent the secondary structural changes induced upon guanidinium hydrochloride-induced unfolding. Taken together, these results imply that Tween 20 protects rFXIII against freeze-thawing- and agitation-induced aggregation primarily by competing with stress-induced soluble aggregates for interfaces, inhibiting subsequent transition to insol. aggregates.

ST Tween 20 aggregation recombinant human factor XIII; freeze thawing aggregation recombinant human factor XIII

IT Aggregates

Aggregation

**Circular dichroism spectroscopy**

**Critical micelle concentration**

ESR spectroscopy

Freeze drying

(Tween 20 effect on freeze-thawing-induced aggregation of recombinant human factor XIII)

IT 9013-56-3, Blood coagulation factor XIII

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU

(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(Tween 20 effect on freeze-thawing-induced aggregation of recombinant  
human factor XIII)

IT 9005-64-5, Tween 20

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Tween 20 effect on freeze-thawing-induced aggregation of recombinant  
human factor XIII)

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Anchordoquy, T; Arch Biochem Biophys 1996, V332, P231 HCAPLUS
- (2) Andrade, J; Adv Polym Sci 1986, V70, P1
- (3) Bam, N; Biotechnol Prog 1996, V12, P801 HCAPLUS
- (4) Bam, N; Pharm Res 1995, V12, P2 HCAPLUS
- (5) Bishop, P; Biochemistry 1990, V29, P1861 HCAPLUS
- (6) Chang, B; J Pharm Sci 1996, V85, P1325 HCAPLUS
- (7) Charman, S; Pharm Res 1993, V10, P954 HCAPLUS
- (8) Claesson, P; Adv Colloid Interface Sci 1995, V57, P161 HCAPLUS
- (9) Cleland, J; J Biol Chem 1992, V267, P3147 HCAPLUS
- (10) Dong, A; In press
- (11) Eckhardt, B; Pharm Res 1991, V8, P1360 HCAPLUS
- (12) Franks, F; Adv Protein Chem 1995, V46, P105 HCAPLUS
- (13) Helenius, A; Methods Enzymol 1979, V56, P734 HCAPLUS
- (14) Ip, A; J Pharm Sci 1995, V84, P1210 HCAPLUS
- (15) Izutsu, K; Biotech Bioeng 1994, V43, P1102 HCAPLUS
- (16) Kurochkin, I; J Mol Biol 1995, V248, P414 HCAPLUS
- (17) Larsen, S; Arch Pharm Chemi Sci Ed 1973, V1, P61
- (18) Maa, Y; Biotech Bioeng 1997, V54, P503 HCAPLUS
- (19) Macritchie, F; Adv Colloid Interface Sci 1986, V25, P341 HCAPLUS
- (20) Medical Economics Co Inc; Physician's Desk Reference 1997
- (21) Nema, S; J Parenter Sci Technol 1993, V47, P76 HCAPLUS
- (22) Nishikido, N; Bull Chem Soc Jpn 1982, V55, P3085 HCAPLUS
- (23) Pikal, M; BioPharm 1990, V3, P26 HCAPLUS
- (24) Pikal, M; Pharm Res 1991, V8, P427 HCAPLUS
- (25) Privalov, P; Crit Rev Biochem Mol Biol 1990, V25, P281 HCAPLUS
- (26) Rinas, U; Biol Chem Hoppe Seyler 1990, V371, P49 HCAPLUS
- (27) Schwartz, M; J Biol Chem 1973, V248, P1395 HCAPLUS
- (28) Semisotnov, G; Biopolymers 1991, V31, P119 HCAPLUS
- (29) Strambini, G; Biophys J 1996, V70, P971 HCAPLUS
- (30) Stryer, L; J Mol Biol 1965, V13, P482 HCAPLUS
- (31) Sukow, W; Biochemistry 1980, V19, P912 HCAPLUS
- (32) Tanford, C; The hydrophobic effect: Formation of micelles and biological membranes 1980
- (33) Thurow, H; Diabetologia 1984, V27, P212 HCAPLUS
- (34) van Den Berg, L; Arch Biochem Biophys 1959, V81, P319 HCAPLUS
- (35) Vogel, V; Protein at Interfaces II: Fundamentals and Applications; ACS Symposium Series 602 1995, P505 HCAPLUS
- (36) Zhang, M; Pharm Res 1996, V13, P643 HCAPLUS

L80 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:137145 HCAPLUS

DN 128:280456

ED Entered STN: 09 Mar 1998

TI **Spectroscopic probes** of the interactions of the dye  
Stains-all with deoxycholate and cholate

AU Goswami, Arup; Kanta Pal, Medini

CS Biophysics, Department of Biochemistry, University of Kalyani,  
Kalyani-741235, India

SO Colloids and Surfaces, B: Biointerfaces (1998), 10(3), 149-159  
CODEN: CSBBEQ; ISSN: 0927-7765

PB Elsevier Science B.V.

DT Journal  
 LA English  
 CC 9-5 (Biochemical Methods)  
 AB The biol. surfactants sodium cholate (NaC) and sodium deoxycholate (NaDC) differ from the normal surfactants such as SDS by having hydrophilic -OH groups in their hydrophobic moieties, and they failed to induce sharp blue shifted metachromasia in the common cationic dyes such as acridine orange, methylene blue, pinacyanol etc. However, both the cholates induce extremely sharp and stable blue-shifted metachromasia in the cyanine dye Stains-all (Stal), at concentrate much below the critical micellar concns. and not

disrupted by the excess of surfactants unless at above the resp. critical micellar concns. Both chiral cholates induce very strong biphasic neg. CD in Stal. At high surfactant dye both NaDC-Stal and NaC-Stal exhibit a second pos. biphasic CD spectrum, indicating the formation of second species of the complexes, not immediately discernible from the resp. absorption spectrum. Though the reported structures of micelles and crystals of NaDC are distinctly different from that of NaC, the induced metachromasia and CD in Stal by the two surfactants are remarkably similar. It is reasonably thought that Stal cations bound at NaC and NaDC are arranged with systematic twists in one sense, responsible for metachromasia and dichroism of the dye aggregates, the formation of NaDC-Stal and NaC-Stal are probably followed by some self organization of the complexes formed in the premicellar range of concns., excess surfactants added to these complexes form just part of the solvent. Only above cmc the micelles start disruption of the dye aggregates. Our results fit well with the helical model of NaDC and the Small's model of NaDC micellar aggregate with the hydrophobic surfaces oriented inside.

ST spectroscopy probe interaction dye Stains all; deoxycholate cholate

IT **Circular dichroism**

**Critical micelle concentration**

UV and visible spectroscopy

(spectroscopic probes of interactions of dye Stains-all with deoxycholate and cholate)

IT 7423-31-6, Stains-all

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)

(spectroscopic probes of interactions of dye Stains-all with deoxycholate and cholate)

IT 302-95-4, Sodium deoxycholate 361-09-1, Sodium cholate

RL: RCT (Reactant); RACT (Reactant or reagent)

(spectroscopic probes of interactions of dye Stains-all with deoxycholate and cholate)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alagni, M; Biopolymers 1993, V33, P1553
- (2) Alagni, M; Colloid Polymer Sci 1985, V263, P160
- (3) Anon; Sigma Catalogue, Biochemicals, Organic Compounds for Research and Diagnostic Reagents 1997
- (4) Baxendale, J; J Phys Chem 1982, V86, P4906 HCAPLUS
- (5) Bean, R; J Phys Chem 1965, V69, P4368 HCAPLUS
- (6) Bomes, S; J Lipid Res 1982, V23, P161
- (7) Budavari, S; An Encyclopedia of Chemicals, Drugs, and Biological, 11th edn 1989
- (8) Campanelli, A; J Phys Chem 1989, V93, P1536 HCAPLUS
- (9) Campbell, Y; J Biol Chem 1983, V258, P11267
- (10) Carey, M; Sterols and Bile Acids 1985, P373
- (11) Chen, M; J Am Chem Soc 1975, V97(8), P2052 HCAPLUS
- (12) Cobbledick, R; Acta Cryst B 1980, V36, P287
- (13) Coello, A; J Phys Chem 1993, V97, P10186 HCAPLUS
- (14) Conte, O; J Phys Chem 1984, V88, P5720



- (15) Ebert, G; Colloidal Systems 1985, P128
- (16) Esposito, G; J Phys Chem 1987, V91, P356 HCAPLUS
- (17) Esposito, G; J Phys Chem 1987, V91, P83 HCAPLUS
- (18) Foersterling, R; Optische anregung Organische Systeme 1966, P55
- (19) Gelben, M; Photochem Photobiol A: Chem 1995, V87, P55
- (20) Giglio, E; J Phys Chem 1988, V92, P2858 HCAPLUS
- (21) Green, M; Anal Biochem 1973, V56, P43 HCAPLUS
- (22) Hofman, A; Annu Rev Med 1967, V18, P333
- (23) Jones, L; J Biol Chem 1979, V254, P539
- (24) Jones, L; J Biol Chem 1981, V256, P11809 HCAPLUS
- (25) Kawamura, H; J Phys Chem 1989, V93(8), P3321 HCAPLUS
- (26) Kay, R; J Phys Chem 1964, V68, P1907
- (27) Kay, R; J Phys Chem 1964, V68, P1907
- (28) Law, K; Photochem Photobiol 1981, V33, P799 HCAPLUS
- (29) Li, G; J Phys Chem 1993, V97, P6745 HCAPLUS
- (30) Mandal, A; J Colloid Interface Sci 1997, V192, P83 HCAPLUS
- (31) Mazar, N; Biochemistry 1979, V18(14), P3064
- (32) Mukherjee, P; J Am Chem Soc 1955, V77, P2937
- (33) Oakenfull, D; J Phys Chem 1977, V81(19), P1838 HCAPLUS
- (34) Pal, M; Histochemie 1971, V27, P36 HCAPLUS
- (35) Pal, M; Indian J Chem 1982, V21A, P599 HCAPLUS
- (36) Pal, M; J Am Chem Soc 1962, V84, P4384
- (37) Pal, M; J Phys Chem 1990, V94, P2557 HCAPLUS
- (38) Pal, M; Makromol Chem 1980, V181, P1459 HCAPLUS
- (39) Sato, H; Chem Phys Lett 1980, V71, P3216
- (40) Small, D; Adv Chem Ser 1968, V84, P31
- (41) Small, D; Biochim Biophys Acta 1969, V176, P178 HCAPLUS
- (42) Tatsuino, N; Bull Chem Soc Jpn 1974, V47(2), P289

L80 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:537650 HCAPLUS

DN 127:201665

ED Entered STN: 23 Aug 1997

TI Effects of temperature and concentration on **bovine lens**  
 $\alpha$ -crystallin secondary structure: a circular dichroism spectroscopic study

AU Farnsworth, Patricia N.; Groth-Vasselli, B.; Greenfield, Norma J.; Singh, Kamalendra

CS Department of Pharmacology and Physiology, UMD-New Jersey Medical School, Newark, NJ, 07103, USA

SO International Journal of Biological Macromolecules (1997), 20(4), 283-291

CODEN: IJBMDR; ISSN: 0141-8130

PB Elsevier

DT Journal

LA English

CC 6-3 (General Biochemistry)

AB Elucidation of the structure of  $\alpha$ -crystallin, the major protein in all vertebrate lenses, is important for understanding its role in maintaining transparency and its function in other tissues under both normal and pathol. conditions. Progress toward a unified consensus concerning the tertiary and quaternary structures of  $\alpha$ -crystallin depends, in part, on an accurate estimation of its secondary structure. For the first time, three algorithms, SELCON, K2D and CONTIN were used to analyze far ultra-violet CD (UV-CD) spectra of bovine lens  $\alpha$ -crystallin to estimate the secondary structure and to determine the effects of temperature and concentration Under all exptl. conditions tested, the analyses show

that  $\alpha$ -crystallin contains 14%  $\alpha$ -helix, 35%  $\beta$ -sheet and the remainder, random coil and turns. The results suggest that